Table 2.
In vitro susceptibilities of ED and FLC alone and in combination against C. albicans.
| Strains | MIC80 of drugsa (μg/ml) | FICIb | |||
|---|---|---|---|---|---|
| Alone | Combination | ||||
| ED/FLC | ED/FLC | ||||
| 24Dc | >128 | >128 | 32 | 2 | 0.266 |
| 28Ic | >128 | >128 | 2 | 2 | 0.031 |
| CA102c | >128 | >128 | 4 | 8 | 0.094 |
| CA901c | >128 | >128 | 4 | 2 | 0.047 |
| CA112869c | >128 | >128 | 4 | 4 | 0.063 |
| CA13d | 64 | 2 | 2 | 0.25 | 0.156 |
| CA21d | 64 | 2 | 2 | 0.25 | 0.156 |
| SC5314d | 32 | 2 | 4 | 0.25 | 0.250 |
ED, eucalyptal D; FLC, fluconazole.
Synergism and antagonism were defined by FICI of ≤ 0.5 and >4, respectively. An FICI index result of >0.5 but ≤ 4 was considered indifferent.
FLC resistant strains.
FLC susceptible strains.